prikaz prve stranice dokumenta Mechanistic View on the Effects of SGLT2 Inhibitors on Lipid Metabolism in Diabetic Milieu
  Download
PDF 1.89 MB
Scientific paper - Review paper
Mechanistic View on the Effects of SGLT2 Inhibitors on Lipid Metabolism in Diabetic Milieu
Journal of Clinical Medicine, 11 (2022), 21; 6544. https://doi.org/10.3390/jcm11216544
Yaribeygi, Habib; Maleki, Mina; Reiner, Željko; Jamialahmadi, Tannaz; Sahebkar, Amirhossein

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Yaribeygi, H., Maleki, M., Reiner, Ž., Jamialahmadi, T. & Sahebkar, A. (2022). Mechanistic View on the Effects of SGLT2 Inhibitors on Lipid Metabolism in Diabetic Milieu. Journal of Clinical Medicine, 11. (21). doi: 10.3390/jcm11216544

Yaribeygi, Habib, et al. "Mechanistic View on the Effects of SGLT2 Inhibitors on Lipid Metabolism in Diabetic Milieu." Journal of Clinical Medicine, vol. 11, no. 21, 2022. https://doi.org/10.3390/jcm11216544

Yaribeygi, Habib, Mina Maleki, Željko Reiner, Tannaz Jamialahmadi and Amirhossein Sahebkar. "Mechanistic View on the Effects of SGLT2 Inhibitors on Lipid Metabolism in Diabetic Milieu." Journal of Clinical Medicine 11, no. 21 (2022). https://doi.org/10.3390/jcm11216544

Yaribeygi, H., et al. (2022) 'Mechanistic View on the Effects of SGLT2 Inhibitors on Lipid Metabolism in Diabetic Milieu', Journal of Clinical Medicine, 11(21). doi: 10.3390/jcm11216544

Yaribeygi H, Maleki M, Reiner Ž, Jamialahmadi T, Sahebkar A. Mechanistic View on the Effects of SGLT2 Inhibitors on Lipid Metabolism in Diabetic Milieu. Journal of Clinical Medicine [Internet]. 2022 November 04 [cited 2024 December 25];11(21). doi: 10.3390/jcm11216544

H. Yaribeygi, M. Maleki, Ž. Reiner, T. Jamialahmadi and A. Sahebkar, "Mechanistic View on the Effects of SGLT2 Inhibitors on Lipid Metabolism in Diabetic Milieu", Journal of Clinical Medicine, vol. 11, no. 21, November 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:843634. [Accessed: 25 December 2024]

Metadata
Title (english)Mechanistic View on the Effects of SGLT2 Inhibitors on Lipid Metabolism in Diabetic Milieu
AuthorHabib Yaribeygi
AuthorMina Maleki
AuthorŽeljko Reiner
AuthorTannaz Jamialahmadi
AuthorAmirhossein Sahebkar
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Medical Microbiology and Parasitology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Medical Microbiology
Abstract (english)
Chronic hyperglycemia induces pathophysiologic pathways with negative effects on the metabolism of most substrates as well as lipids and lipoproteins, and thereby induces dyslipidemia. Thus, the diabetic milieu is commonly accompanied by different levels of atherogenic dyslipidemia, which is per se a major risk factor for subsequent complications such as atherosclerosis, coronary heart disease, acute myocardial infarction, ischemic stroke, and nephropathy. Therefore, readjusting lipid metabolism in the diabetic milieu is a major goal for preventing dyslipidemia-induced complications. Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a class of relatively newly introduced antidiabetes drugs (including empagliflozin, canagliflozin, dapagliflozin, etc.) with potent hypoglycemic effects and can reduce blood glucose by inducing glycosuria. However, recent evidence suggests that they could also provide extra-glycemic benefits in lipid metabolism. It seems that they can increase fat burning and lipolysis, normalizing the lipid metabolism and preventing or improving dyslipidemia. Nevertheless, the exact mechanisms involved in this process are not well-understood. In this review, we tried to explain how these drugs could regulate lipid homeostasis and we presented the possible involved cellular pathways supported by clinical evidence.
Keywords (english)
Languageenglish
Publication typeScientific paper - Review paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleJournal of Clinical Medicine
Numberingvol. 11, no. 21, 6544
e-ISSN2077-0383
DOIhttps://doi.org/10.3390/jcm11216544
URN:NBNurn:nbn:hr:105:843634
Publication2022-11-04
Document URLhttps://www.mdpi.com/2077-0383/11/21/6544
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2023-07-13 07:16:38